Pre-Treatment Carbohydrate Antigen 19-9 Does Not Predict the Response to Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer

HPB - United Kingdom
doi 10.1111/hpb.12448
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients With Pancreatic Cancer

Oncology
MedicineCancer ResearchOncology
2006English

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Response to Preoperative Therapy in Localized Pancreatic Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

A Case of Carbohydrate Antigen 19-9 Producing Gastric Cancer With Leucocytosis

Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
2000English

A Case Report of Carbohydrate Antigen 19-9 Producing Advanced Gastric Cancer

Cancer and Clinical Oncology
2016English

Response to Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

P53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer

2003English

Carbohydrate Antigen 19-9 (CA19-9) Represents the Disease Activity of Nontuberculous Mycobacteria

Mycobacterial Diseases
2015English

Sustained CA19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival

Oncologist
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy